Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration ...

Clinical and genomic characteristics of lung cancer concomitant chronic obstructive pulmonary disease (COPD). Noninferiority multicenter prospective randomized controlled study of rectal cancer T2–T3s ...

Previous studies indicate that capecitabine exhibits less favorable tolerability among patients with colorectal cancer in the United States, with women facing an increased risk for toxicity.

For the first time, researchers have shown that a chemotherapy regimen of capecitabine plus oxaliplatin (CAPOX) is as safe and effective as infusional 5-fluorouracil/folinic acid plus oxaliplatin ...

The researchers identified 3,263 events of disease recurrence or death in 12,834 patients; in the overall study population, the noninferiority of 3 months versus 6 months of treatment was not ...

Six months of adjuvant chemotherapy with either FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine and oxaliplatin) has remained an international standard of care in patients ...

January 22 (Orlando, Florida) — In contrast to some previous studies that found no benefit with newer chemotherapy regimens in elderly colorectal cancer patients, a randomized phase 3 trial showed ...

Following reporting of severe diarrhoea and dehydration with capecitabine 2000 mg m –2 per day plus oxaliplatin every 3 weeks (CAPOX 2000) in 2006, we instituted a policy change to reduce capecitabine ...

SUZHOU, China, June 1, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, ...

Please provide your email address to receive an email when new articles are posted on . For years, standard treatment for patients with stage III colon cancer has been adjuvant chemotherapy for 6 ...

Zolbetuximab is a new drug for the treatment of gastric cancer. In trials, it showed significant improvement in survival rates. The FDA is expected to make an approval decision on the drug in January ...